Press "Enter" to skip to content

New patent for Fresenius Kabi drug LEVOTHYROXINE SODIUM

0
Copyright © DrugPatentWatch. Originally published at New patent for Fresenius Kabi drug LEVOTHYROXINE SODIUM

Annual Drug Patent Expirations for LEVOTHYROXINE+SODIUM
Annual Drug Patent Expirations for LEVOTHYROXINE+SODIUM

Levothyroxine Sodium is a drug marketed by Teva Pharms Usa Inc, Dr Reddys, Fresenius Kabi Usa, Maia Pharms Inc, Par Sterile Products, Piramal Critical, Custopharm Inc, Accord Hlthcare, Amneal, Lupin, Merck Kgaa, and Mylan and, and is included in fourteen NDAs. It is available from nineteen suppliers. There are five patents protecting this drug and two Paragraph IV challenges.

Drug patent litigation for LEVOTHYROXINE SODIUM.

This drug has four patent family members in three countries.

The generic ingredient in LEVOTHYROXINE SODIUM is levothyroxine sodium. Nineteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the levothyroxine sodium profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at New patent for Fresenius Kabi drug LEVOTHYROXINE SODIUM
    DrugPatentWatch - Make Better Decisions